Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for EVX-01 + pembrolizumab in Melanoma. The expected timing is based on the latest available company guidance and may change.
04/17/26:- New Ph2 immune-response data to be presented at AACR Apr 22, 2026. Three-year clinical data expected H2 2026. 05/07/26:- Ph2 AACR data showed 86% target response; one-year extension completed; three-year data expected H2 2026. 07/17/26:- Ph2 three-year efficacy data to be presented at ESMO on Oct 24, 2026. 08/20/26:- Three-year Ph2 efficacy data will be presented at ESMO on October 24, 2026.
Verification
Confirm timing and program details against the company announcement or filing.